Danuglipron

Source: Wikipedia, the free encyclopedia.
Danuglipron
Clinical data
Other namesPF-06882961
Legal status
Legal status
  • Investigational
Identifiers
  • 2-[[4-[6-[(4-Cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid
JSmol)
SMILES
  • C1CO[C@@H]1CN2C3=C(C=CC(=C3)C(=O)O)N=C2CN4CCC(CC4)C5=NC(=CC=C5)OCC6=C(C=C(C=C6)C#N)F
  • InChI=1S/C31H30FN5O4/c32-25-14-20(16-33)4-5-23(25)19-41-30-3-1-2-26(35-30)21-8-11-36(12-9-21)18-29-34-27-7-6-22(31(38)39)15-28(27)37(29)17-24-10-13-40-24/h1-7,14-15,21,24H,8-13,17-19H2,(H,38,39)/t24-/m0/s1
  • Key:HYBAKUMPISVZQP-DEOSSOPVSA-N

Danuglipron is a small-molecule

diabetic control. The most commonly reported adverse events were nausea, diarrhea, and vomiting.[2][3] However, in April 2025, Pfizer announced it would abandon further development of Danuglipron due to unpredictable liver toxicity.[4]

See also

References

  1. PMID 35647711
    .
  2. PMID 37213102
    .
  3. ^ Constantino AK (2023-12-02). "Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops". CNBC. Retrieved 2023-12-03.
  4. ^ Constantino AK (April 14, 2025). "Pfizer scraps daily weight loss pill after liver injury in one patient". CNBC.
gastrointestinal system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Danuglipron&oldid=1296300162"